Ken-Ichi Oinuma

Ken-Ichi Oinuma

Auto-generated profile, based on publicly available information

Ken-Ichi Oinuma

Department of Bacteriology, Osaka Metropolitan University Graduate School of Medicine

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2023 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
HNHIROKI NAMIKAWA
HIROKI NAMIKAWA
KOKen-Ichi Oinuma
Ken-Ichi Oinuma
KYKoichi Yamada
Koichi Yamada
YKYukihiro Kaneko
Yukihiro Kaneko
HKHiroshi Kakeya
Hiroshi Kakeya
TSTaichi Shuto
Taichi Shuto

23 December 2022 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
MTMitsunori Tohda
Mitsunori Tohda
KOKen-Ichi Oinuma
Ken-Ichi Oinuma
ASArata Sakiyama
Arata Sakiyama
TTTaishi Tsubouchi
Taishi Tsubouchi
MNMamiko Niki
Mamiko Niki
TKTomoya Kawaguchi
Tomoya Kawaguchi
In hypervirulent Klebsiella pneumoniae (hvKP), the hypermucoviscous capsule is known to be a major virulence determinant. We previously discovered that rifampicin (RFP), a bactericidal drug that binds to and inhibits the β subunit of RNA polymerase (RpoB), elicits anti-mucoviscous activity against hvKP by suppressing rmpA, a regulator of capsule production. Here, we aimed to determine whether RFP exerts this effect at sub-growth-inhibitory concentrations via its binding to RpoB. Five spontaneous RFP-resistant mutants (R1-R5) were prepared from an hvKP clinical isolate and subjected to whole genome sequencing and mucoviscosity analyses. Subsequently, a two-step allelic exchange procedure was used to create a rpoB mutant R6 and revertants with wild-type rpoB from R1-R5 (named R1'-R5'). Transcription levels of rmpA and the capsular polysaccharide polymerase gene magA and capsule thickness of R1-R5 and R1'-R5' grown without or with RFP were evaluated by quantitative reverse transcription polymerase chain reaction and microscopic observation using India ink staining. R1-R5 all had non-synonymous point mutations in rpoB and were highly resistant to the bactericidal effects and anti-mucoviscous activity of RFP. While the properties of R6 were similar to those of R1-R5, the responses of R1'-R5' to RFP were identical to those of the wild type. rmpA and magA transcription levels and capsule thickness correlated well with the mucoviscosity levels. RFP exerts anti-mucoviscous activity by binding to RpoB. The mechanism of how this causes rmpA suppression remains to be explored.

1 January 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
TATomonori Akiyama
Tomonori Akiyama
MIMisaki Ishii
Misaki Ishii
ATAtsushi Takuwa
Atsushi Takuwa
KOKen-Ichi Oinuma
Ken-Ichi Oinuma
YSYasuyuki Sasaki
Yasuyuki Sasaki
SYShunsuke Yajima
Shunsuke Yajima

20 May 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ASArata Sakiyama
Arata Sakiyama
CSChaogetu Saren
Chaogetu Saren
YKYukihiro Kaneko
Yukihiro Kaneko
KOKen-Ichi Oinuma
Ken-Ichi Oinuma
There exists decades-old evidence that some mycobacteria, including Mycobacterium avium and Mycobacterium smegmatis, produce hydrazidase, an enzyme that can hydrolyze the first-line antitubercular agent isoniazid. Despite its importance as a potential resistance factor, no studies have attempted to reveal its identity. In this study, we aimed to isolate and identify M. smegmatis hydrazidase, characterize it, and evaluate its impact on isoniazid resistance. We determined the optimal condition under which M. smegmatis produced the highest amount of hydrazidase, purified the enzyme by column chromatography, and identified it by peptide mass fingerprinting. It was revealed to be PzaA, an enzyme known as pyrazinamidase/nicotinamidase whose physiological role remains unknown. The kinetic constants suggested that this amidase with broad substrate specificity prefers amides to hydrazides as a substrate. Notably, of the five tested compounds, including amides, only isoniazid served as an efficient inducer of pzaA transcription, as revealed by quantitative reverse transcription PCR. Moreover, high expression of PzaA was confirmed to be beneficial for the survival and growth of M. smegmatis in the presence of isoniazid. Thus, our findings suggest a possible role for PzaA, and other hydrazidases yet to be identified, as an intrinsic isoniazid resistance factor of mycobacteria.

11 February 2026 in mBio
Verified
Journal Article
Open access
CSChaogetu Saren
Chaogetu Saren
KOKen-Ichi Oinuma
Ken-Ichi Oinuma
TTTaishi Tsubouchi
Taishi Tsubouchi
ASArata Sakiyama
Arata Sakiyama
MSMasato Suzuki
Masato Suzuki
YKYukihiro Kaneko
Yukihiro Kaneko
Acinetobacter baumannii is an opportunistic pathogen in which capsule production is closely linked to immune evasion and environmental persistence. Recent studies have described two seemingly contradictory phenomena—increasing prevalence of capsule-overproducing clinical isolates and frequent isolation of capsule-deficient variants. The biological significance of these phenomena remains unclear. In this study, we analyzed a clinical isolate, OCU_Ac16b, which spontaneously gives rise to two phenotypically distinct variants: the L type forming large colonies with a prominent hypercapsule (>1 µm thick), and the S type forming small colonies with a substantially reduced or absent capsule. When L-type cells were cultured in test tubes under low-shaking conditions, S-type variants reproducibly emerged, constituting approximately 40%–80% of the population within 24 h. Whole-genome sequencing revealed that this conversion is driven by distinct mutations in the capsular polysaccharide synthesis cluster, including insertion sequence insertions and a single-nucleotide deletion. Dilution experiments demonstrated that L-to-S conversion mutations arise de novo during liquid culture at sufficiently high rates to account for the rapid and reproducible emergence of S-type variants. Phenotypic characterization demonstrated a biological trade-off, with L-type cells exhibiting enhanced resistance to serum killing, desiccation, and certain β-lactam antibiotics, whereas S-type cells showed superior surface attachment, increased biofilm formation, and a growth advantage under oxygen-limited conditions. Our findings uncover a highly reproducible, mutation-driven capsule switching mechanism that enables rapid phenotypic adaptation to changing environments. This phenotypic heterogeneity has significant implications for pathogenesis, persistence, diagnostic evaluation, and clinical management. IMPORTANCE: Acinetobacter baumannii is a clinically important opportunistic pathogen that exhibits striking phenotypic diversity. In particular, some clinical isolates produce unusually thick capsules, which are thought to contribute to immune evasion and persistence, while others lack the capsule altogether. However, the biological significance of these contrasting phenotypes has remained unclear. We analyzed a clinical isolate that spontaneously gives rise to capsule-deficient variants from a hypercapsulated form. We found that the conversion is driven by spontaneous mutations in capsule biosynthesis genes, including de novo mutations arising during liquid culture, while the expansion of capsule-deficient cells is promoted under oxygen-limited conditions. The two variants differed in serum resistance, desiccation tolerance, growth characteristics, and antibiotic responses, revealing a trade-off between protective barriers and environmental adaptability. These findings provide new insights into how A. baumannii may balance survival strategies through genetic and phenotypic heterogeneity, with potential implications for diagnosis, treatment, and bacterial persistence in clinical settings.

21 December 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
ASArata Sakiyama
Arata Sakiyama
KOKen-Ichi Oinuma
Ken-Ichi Oinuma
YKYukihiro Kaneko
Yukihiro Kaneko